Introduction: Bacterial urinary tract infections (UTIs) are very common complications in renal transplant recipients (RTRs). Methodology: This study is a follow-up to a previous investigation of post-renal transplant UTIs, which led to changes in the antibacterial agents used for prophylaxis and its duration. In this retrospective study of the medical records of 86 RTRs, the incidence, risk factors, causative bacteria, and duration prophylaxis were investigated. Results: The average age of the RTRs was 41.55 ± 14.06 years, and two-thirds of them were males. A total of 57.3% of the RTRs received cadaveric kidneys; the rest received kidneys from living related donors. The prescribed regimen (one month or three months of cotrimoxazole and norfloxacin) was completed by 75% of the RTRs. The incidence of UTIs in the RTRs who received this prophylaxis was 32.3%, which was significantly lower than the incidence with norfloxacin alone (56%). Female gender was found to be a risk factor for postrenal transplant UTIs. Escherichia coli was the most common pathogen (51.7%), followed by Klebsiella and Enterobacter (17.2% each). Most UTIs (86.2%) were detected within the first post-transplant month. Conclusions: There was no clear advantage to prescribing antibacterial prophylaxis for three months versus one month, as 86.2% of the UTIs occurred within the first month post-transplant regardless of prophylaxis duration. Using co-trimoxazole/norfloxacin compared to norfloxacin alone did positively affect patient outcome by reducing the incidence of UTIs. This study recommends antimicrobial sensitivity-guided modification of the antibacterial agents used for prophylaxis rather than extension of its duration.
Introduction
Bacterial urinary tract infections (UTIs) are the most common infections in renal transplant recipients (RTRs) and are a major cause of morbidity [1] . The rate of bacterial UTIs in renal transplant recipients has been reported to be as a low as 6% [1] and as high as 98% [2] . Recently, we reported a pilot study that estimated the rate of UTIs in this population to be 56% [3] . In addition to the increasing mortality and morbidity due to UTIs in RTRs [4, 5] , septicemia is a common complication that can result in graft rejection [6] . The onset of bacterial UTIs post-renal transplant has been reported by many studies, but as in the case of reported rates of infection, a consensus has not been reached. There are numerous reports stating that UTIs occur most commonly with the first three to six months [7] [8] [9] [10] following transplant, while many others show that the highest incident for UTIs is one month post-transplant [3, 11, 12] . RTRs have multiple risk factors for acquiring UTIs post-renal transplant. A front runner is immunosuppressive therapy, which can lead to a higher incidence of infection [13] [14] [15] and different infection epidemiology [16] . It has also been shown that catheterization for longer than two days is an important risk factor [17] . Additionally, female gender has been cited frequently as another risk factor [3, 7, 14, 18, 19] . Due to the relatively high rates and serious consequences of bacterial UTIs in renal transplant recipients in addition to the fact that RTRs are immunocompromised, it is important to implement an antibacterial prophylaxis regimen in renal transplant programs.
Here we report the incidence of UTIs in RTRs who were put on a prophylaxis regimen consisting of cotrimoxazole (sulfamethoxazole/trimethoprim) and norfloxacin. This work builds on our previous pilot study where norfloxacin was the only prophylactic agent used.
Methodology

Study design
This was a retrospective study that was approved by the Institutional Review Board (IRB) of King Abdullah International Research Center (KAIMRC), National Guard Health Affairs, Riyadh, Saudi Arabia. The patient charts of 86 adult renal transplant recipients (RTRs) in the renal transplant unit at King Abdulaziz Medical City at the National Guard Health Affairs were reviewed. Only 82 patient charts were included in the study; the other four charts were excluded because the patients were not adults. The inclusion rate was 95.4%. The patients' age, gender, source of the transplanted kidney (cadaver or living relative), serum creatinine at 1, 3, 6 and 12 months, and the presence of bacterial UTI at 1 and 3 months were recorded. Bacterial UTI was diagnosed based on urine cultures positive for bacterial growth greater than 105 CFU/mL. White blood cell (WBC) counts were also obtained. The Infectious Diseases Society of America has not put restrictions on the screening or treatment protocols in asymptomatic bacteriuria in renal transplant recipients [20] . All the RTRs received cefazolin 1 g preoperatively and were supposed to adhere to a postoperative prophylaxis regimen that consisted of 400 mg norfloxacin daily and 960 mg cotrimoxazole (800 mg sulfamethoxazole/160 mg trimethoprim) every other day for three months. In addition to the antibacterial agents, the patients received the following immunosuppressant combination: prednisone, mycophenolic acid, and cyclosporine or tacrolimus.
Statistical analysis
The results were analyzed using Pearson correlation, one-way ANOVA and Chi-square depending on the kind of variables (i.e., continuous vs. discrete variables) as implemented in SPSS version 20 (IBM, USA). In all analyses, a p-value < 0.05 was considered statistically significant.
Urine culture
The method described by Alkatheri was followed [3] . A 0.001 mL (small) calibrated inoculating loop was dipped into the urine sample and then was allowed to drain. A loopful was delivered to the middle of one side of a blood agar/MacConkey biplate, making one vertical streak, then a cross streak at 90°. This streaking was repeated for the second side. The plate was then promptly incubated at 35°C to 37°C aerobically overnight. After 24 hours, the number of colonies on the media in each plate was recorded. The species with > 50 colonies in the plates showing potentially significant growth were identified and subjected to antimicrobial susceptibility testing. If the species were mixed, the predominant species (> 100 colonies) were identified and subjected to antimicrobial susceptibility testing. All cultures exhibiting significant growth were identified using VitekII-XL system (BioMérieux, Marcy L'Étoile, France).
Results
The characteristics of the sample and incidence of UTIs are shown in Table 1 (42.7%) . In the patient records of the sample, it was found that 58.5% of the RTRs received three months of prophylaxis (norfloxacin and cotrimoxazole), 17.1 % received one month of prophylaxis, and the remaining 24.4% received less than one week of prophylaxis. The prevalence of UTIs in the sample was 35.4%, as shown in Table 1 .
The incidence of UTIs according to gender, age, source of kidney, and duration of prophylaxis is summarized in Table 2 . There was a significant association between gender and the incidence of UTIs, as 54.8% of the female RTRs developed UTIs compared to 27.5% of the males (p < 0.05). Although there was no significant association between incidence of UTIs and age (p > 0.05), the incidence of UTIs was the highest among RTRs of the oldest age group (≥ 56 years of age). In this group, 56.3% developed UTIs compared to 27.3%, 27.6%, and 40.0% for age groups ≤ 35, 36-45 and 46-55 years, respectively. Table 3 . No statistical correlations could be found with any of the variables; a total sample size of 29 UTIs greatly reduces the value of statistical data. With regard to gender, the vast majority (87.6%) of female RTRs who developed UTIs either received prophylaxis for less than one week (43.8%) or for three months (43.8%), while the majority (76.9%) of male RTRs who developed UTIs received prophylaxis for three months. Similarly, all the RTRs ≥ 56 years of age who developed UTIs received prophylaxis for either less than one week or for three months, while the majority (78.8%) of the RTRs ≤ 35 years of age who developed UTIs received prophylaxis for three months. The trend continued with regard to the source of the transplanted kidney, as the vast majority (≥ 90%) of RTRs who developed UTIs received prophylaxis for either less than one week or for three months, regardless of the source of the kidney. Table 3 shows that most of the UTIs occurred during the first month post-transplant (86.2%), regardless of the duration of prophylaxis. More details are shown in Table 4 , which summarizes the prevalence of UTI causative bacteria according to time of detection, whether it was during the first month or third month post-transplant. Half of the detected UTIs were caused by E. coli, followed by Klebsiella and Enterococcus (16.1% each). For E. coli, 86.7% of the cases were detected within one month post-transplant, while 60% of Klebsiella infections and all the enterococcal infections were detected within one month post-transplant. Furthermore, the bacterial UTIs caused by rest of the causative agents (Acromonas, Acintobacter, Citrobacter, and P. aeruginosa) were all detected within one month post-transplant. It must be mentioned here that in all UTI cases, the causative agents were resistant to the agents used in prophylaxis; most of these infections were treated with alternative agents according to the antibacterial susceptibility results of each individual case.
The distribution of three major causative bacteria (E. coli, Klebsiella, and Enterococcus) according to gender, age, source of kidney, and duration of prophylaxis is shown in Table 5 . In this context, descriptive statistics show some interesting trends. It can be seen that 73.3% of the E. coli cases were detected in females, while 80.0% of both Klebsiella and Enteroccus cases were detected in males. With regard to age, no meaningful relation with UTI causative bacteria was observed. E. coli caused most of the infections in RTRs who received living related kidneys; it caused half of the infections in the RTRs who received cadaveric kidneys. It was found that 93.4% of the E. coli infections occurred in RTRs who received either less than one week of prophylaxis or three months of prophylaxis (46.7% for each), and all the infections caused by Klebsiella occurred in the same groups (40% vs. 60, respectively).
Finally, comparing the incidence of UTIs in the previous pilot study by Alkatheri [3] with this current work shows that there was a significant reduction (p < 0.5) in the overall rate, from 56% when only norfloxacin was used to 32.3% among those who received a combination of norfloxacin and cotrimoxazole (Table 6 ). 
Discussion
Although all the RTRs in the sample were supposed to receive either one or three months of antibacterial post-transplant prophylaxis of cotrimoxazole and norfloxacin, 16.4% of them took it for less than one week; these patients can, therefore, be considered not to have received prophylaxis. This is consistent with the literature, which shows rates of patient non-adherence to post-transplant medication of 8%-14% [21, 22] . These figures are for non-adherence to medication in the post-transplant period in general. Unfortunately, we could not find data specific to nonadherence to antibacterial prophylaxis. Although not investigated in the current study, there can be many causes for non-adherence to antibacterial prophylaxis. Weng et al. found that non-adherence in RTRs was associated with depression, being out of medications, finding it hard to remember when to take medications, or being short of money [21] . It is not clear whether any of these factors applies to the current population, and hence it is better not to speculate about the causes of non-adherence without conducting a special study to probe this problem in the current clinical setting. With regard to risk factors to UTIs in RTRs, the results showed that female gender is a risk factor, which is in accordance with many reports in the literature [3, 7, 14, 18, 19] and is consistent with our pilot study [3] . Age was not found to be a statistically significant risk factor in this current study, although the incidence of UTIs seemed to be highest in age groups ≥ 56 years and 46-55 years. There is less agreement on age than on gender with regard to UTIs in RTRs. While Gołębiewska et al. concluded that age is not a risk factor [19] , Sorto et al. found it to be a risk factor for developing UTIs in RTRs [23] . The source of the transplanted kidney was also not found to be a risk factor in the current study. As in the case of age, the literature pertaining to risk factors of UTIs in RTRs is not in agreement about the effect of the source of the transplanted kidney. Some studies found a significant association, although not fully explained, between incidence of UTIs and receiving a cadaveric kidney [24] [25] [26] [27] . Interestingly, a recent report found that even kidneys from infected living donors who are receiving appropriate antibacterial treatment are not a risk factor [28] . There was no significant association between the duration of prophylaxis and the incidence of UTIs. The rate of UTIs in RTRs who received one month of antibacterial prophylaxis was 50% less than in those who received three months of antibacterial prophylaxis. This is interesting in many aspects. First, all the RTRs who received one or three months of prophylaxis were covered for the first month posttransplant. Second, 25 of the 29 UTI cases were detected within the first month post-transplant. Third, three out of the four cases who developed UTIs after three months received prophylaxis for three months. Finally, the causative agents in all the reported UTIs were resistant to the agents used for prophylaxis. The final point might also explain why UTI incidence in the group who received less than one week of prophylaxis was comparable to that of those who received three months of prophylaxis. These interpretations lead to the conclusion that there are no clear benefits to extending the prophylaxis to three months. The literature is greatly divided on the proper duration of prophylaxis. Khosroshahi et al. recommended the use of co-trimoxazole (1,600/320 mg) for one month as prophylaxis [29] , while Golebiewska et al. recommended amoxicillinclavulanate or ciprofloxacin for the same duration [19] . On the other hand, many researchers have found that prophylaxis for three to six month post-transplant can significantly reduce incidence of UTIs in RTRs [30] [31] [32] [33] . As seen earlier, there was significant reduction in UTIs when two agents (norfloxacin and co-trimoxazole) were used as prophylaxis compared to when only one agent (norfloxacin) was used. Many recent reports have described the use of combinations as prophylaxis, including ciprofloxacin/co-trimoxazole [34] [35] [36] , ceftriaxone/co-trimoxazole [19] , and cefotaxime/co-trimoxazole [11] . Co-trimoxazole, which is present in all these combinations, has been considered a routine agent in the antibacterial prophylaxis in RTRs [29] . Furthermore, the issue of antibacterial prophylaxis has been debated, with more than one report concluding that it has no clear benefits [37] [38] [39] [40] [41] .
Serum creatinine levels were approximately 20%-25% higher in RTRs who developed UTIs, but this increase was not statistically significant. Earlier reports have found that higher serum creatinine levels six months post-transplant are associated with high rates of UTIs [42] .
The vast majority of UTIs occurred within the first month post-transplant, which is in agreement with our pilot study [3] and other reports in the literature [11, 12, 43] . Still, some other studies found that the highest incidence of UTIs was three to six month posttransplant [7] [8] [9] [10] . This discrepancy can be due to differences in antibacterial and immunosuppressive prophylaxis regimens. E. coli was the causative organism in almost 50% of the reported UTIs in the study, and the vast majority of those occurred in the first moth post-transplant. These results are also consistent with many literature reports, including our pilot study [19, 44, 45] . Senger et al. detected cotrimoxazole-resistant E. coli in three-quarters of the RTRs who were receiving the agent as prophylaxis [35] . This, in addition to the fact that 87% of the infections occurred in the first month post-transplant, leads to the conclusion that most of the UTIs detected in this study were not due to the effect of the immunosuppressive therapy, as its effect is not maximized until the sixth month post-transplant [6] . Although P. aeruginosa is usually a second major cause of UTIs in general [46] , Klebsiella [47, 48] and Enterococcus [16] have been found to be very common in RTRs. Here, Klebsiella and Enterococcus caused almost one-third of all UTIs, 80% of which occurred in the first month post-transplant. The distribution of causative agents according to onset of infection, gender, and source of transplanted kidneys is highly interesting, though no supporting literature evidence or explanation was found.
In conclusion, the current work has shown that there was a clear advantage to using a combination of norfloxacin/co-trimoxazole over using norfloxacin alone. On the other hand, the results showed that no clear benefits were gained from the extension of the antibacterial prophylaxis in RTRs for more than one month post-transplant. Since we found that most of the infections detected in the RTRs who received prophylaxis were caused by strains that are resistant to the agents in the combination, it is recommended that the antimicrobial sensitivity results in all these patients be studied carefully to develop a proper treatment regimen or to modify the agents used in the prophylaxis regimen rather than to extend the prophylaxis duration beyond one month posttransplant.
